Hitting the Gas: Quantitative Cell-based Bioassays to Advance Immunotherapy Programs Targeting Co-stimulatory Immune Checkpoint Receptors
Part # PS361
Jun Wang, Michael Beck, Jamison Grailer, Jim Hartnett, Julia Gilden, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
We have developed a portfolio of functional cell-based reporter bioassays to measure the activity of biologics drugs designed to target immune checkpoint receptors including co-inhibitory (e.g. PD-1, CTLA-4, LAG-3, TIM-3) and co-stimulatory (e.g. 4-1BB, GITR, OX40, CD40, ICOS, CD28) receptors. These bioassays consist of stable cell lines that express luciferase under the precise control of receptor-mediated intracellular signals. Here we describe the application of MOA-based immune checkpoint co-stimulatory receptor bioassays for biologics drug discovery, development, potency and stability studies.
Printed in USA.